Manuela Rabaglio

7.6k citations
87 papers · 2.1k · h-index 22

Impact in

  • Cancer Research top 2%
    • Breast Cancer Treatment Studies
  • Oncology top 2%
    • HER2/EGFR in Cancer Research
    • Cancer Risks and Factors
    • Cancer Immunotherapy and Biomarkers

Papers in

  • Genetics 33
    • Estrogen and related hormone effects 19
    • BRCA gene mutations in cancer 12
  • Cancer Research 26
    • Breast Cancer Treatment Studies 17
Co-authors
Alan S. Coates (22 shared papers)Aron Goldhirsch (22 shared papers)Richard D. Gelber (19 shared papers)Karen N. Price (14 shared papers)Beat Thürlimann (13 shared papers)Marco Colleoni (23 shared papers)John Forbes (6 shared papers)Ian Smith (7 shared papers)
Journals
Journal of Clinical Oncology (18 papers)Annals of Oncology (10 papers)Cancer Research (8 papers)Cancers (4 papers)The Breast (3 papers)
Partner nations
SwitzerlandUnited StatesItaly

In The Last Decade

Manuela Rabaglio

80 papers receiving 2.1k citations

Peers

Manuela Rabaglio
Comparison fields: 5 of 85
  • Cancer Research 648
  • Oncology 867
  • Family Practice 55
  • Genetics 539
  • Pulmonary and Respiratory Medicine 438
Replace Monica Castiglione with:
Monica Castiglione Switzerland
G Hoctin-Boes Netherlands
J. N. Ingle United States
Günther Gruber Switzerland
Eduardo R. Pajon United States
Ted Vandenberg Canada
Marc Thill Germany
A. De Matteis Italy
Christoph Tausch Switzerland
D. Amoroso Italy
Manuela Rabaglio relative to Monica Castiglione Switzerland Monica Castiglione's profile →
Citations per field
00.5×2×3.0×
Monica Castiglione · 1×
Citations per year

Countries citing papers authored by Manuela Rabaglio

Since Specialization
Citations

This map shows the geographic impact of Manuela Rabaglio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Manuela Rabaglio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Manuela Rabaglio more than expected).

Fields of papers citing papers by Manuela Rabaglio

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Manuela Rabaglio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Manuela Rabaglio. The network helps show where Manuela Rabaglio may publish in the future.

Co-authors

The 25 scholars most cited alongside Manuela Rabaglio, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Manuela Rabaglio Line = papers co-authored together Manuela Rabaglio links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 87 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up
The Lancet Oncology ·Meredith M. Regan, Patrick Neven, Anita Giobbie‐Hurder, Aron Goldhirsch, Bent Ejlertsen, L. Mauriac, John Forbes, Ian Smith, István Láng, Andrew Wardley, Manuela Rabaglio, Karen N. Price, Richard D. Gelber, Alan S. Coates, Beat Thürlimann
2011268
2
Treatment Adherence and Its Impact on Disease-Free Survival in the Breast International Group 1-98 Trial of Tamoxifen and Letrozole, Alone and in Sequence
Journal of Clinical Oncology ·Jacquie Chirgwin, Anita Giobbie‐Hurder, Alan S. Coates, Karen N. Price, Bent Ejlertsen, Marc Debled, Richard D. Gelber, Aron Goldhirsch, Ian Smith, Manuela Rabaglio, John Forbes, Patrick Neven, István Láng, Marco Colleoni, Beat Thürlimann
2016170
3
Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial
Annals of Oncology ·Manuela Rabaglio, Zijie Sun, Karen N. Price, Monica Castiglione‐Gertsch, Hanne Hawle, Beat Thürlimann, Henning T. Mouridsen, Mario Campone, JF Forbes, Robert Paridaens, Marco Colleoni, Tadeusz Pieńkowski, Jean‐Marie Nogaret, István Láng, Ian Smith, Richard D. Gelber, Aron Goldhirsch, Alan S. Coates
2009137
4
Safety evaluation of nivolumab added concurrently to radiotherapy in a standard first line chemo-radiotherapy regimen in stage III non-small cell lung cancer—The ETOP NICOLAS trial
Lung Cancer ·Solange Peters, Enriqueta Felip, Urania Dafni, Claus Belka, Matthias Gückenberger, Antonio Irigoyen López, Ernest Nadal, (unknown), Hansjörg Vees, Miklos Pless, Alex Martínez‐Martí, Amanda Tufman, Maarten Lambrecht, Nicolaus Andratschke, Anne‐Christine Piguet, Marie Kassapian, Heidi Roschitzki‐Voser, Manuela Rabaglio, Rolf A. Stahel, Johan Vansteenkiste, Dirk De Ruysscher
2019127
5
Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
Journal of Thoracic Oncology ·Rafał Dziadziuszko, Egbert F. Smit, Urania Dafni, Juergen Wolf, Bartosz Wasąg, Wojciech Biernat, Stephen P. Finn, Roswitha Kammler, Zoi Tsourti, Manuela Rabaglio, Barbara Ruepp, Heidi Roschitzki‐Voser, Rolf A. Stahel, Enriqueta Felip, Solange Peters
2019111
6
Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial
Annals of Oncology ·L. Mauriac, Aparna Keshaviah, Marc Debled, Henning T. Mouridsen, John Forbes, Beat Thürlimann, R. Paridaens, Alain Monnier, István Láng, Andrew Wardley, Jean‐Marie Nogaret, RD Gelber, Monica Castiglione‐Gertsch, K.N. Price, Alan S. Coates, Ian Smith, Giuseppe Viale, Manuela Rabaglio, N. Zabaznyi, Aron Goldhirsch
2007106
7
Obesity and Risk of Recurrence or Death After Adjuvant Endocrine Therapy With Letrozole or Tamoxifen in the Breast International Group 1-98 Trial
Journal of Clinical Oncology ·Marianne Ewertz, Kathryn P. Gray, Meredith M. Regan, Bent Ejlertsen, Karen N. Price, Beat Thürlimann, Hervé Bonnefoi, John Forbes, Robert Paridaens, Manuela Rabaglio, Richard D. Gelber, Marco Colleoni, István Láng, Ian E. Smith, Alan S. Coates, Aron Goldhirsch, Henning T. Mouridsen
2012103
8
Cholesterol, Cholesterol-Lowering Medication Use, and Breast Cancer Outcome in the BIG 1-98 Study
Journal of Clinical Oncology ·Signe Borgquist, Anita Giobbie‐Hurder, Thomas P. Ahern, Judy E. Garber, Marco Colleoni, István Láng, Marc Debled, Bent Ejlertsen, Roger von Moos, Ian C. P. Smith, Alan S. Coates, Aron Goldhirsch, Manuela Rabaglio, Karen N. Price, Richard D. Gelber, Meredith M. Regan, Beat Thürlimann
2017100
9
Letrozole Compared With Tamoxifen for Elderly Patients With Endocrine-Responsive Early Breast Cancer: The BIG 1-98 Trial
Journal of Clinical Oncology ·Diana Crivellari, Zhuoxin Sun, Alan S. Coates, Karen N. Price, Beat Thürlimann, Henning T. Mouridsen, L. Mauriac, John Forbes, Robert Paridaens, Monica Castiglione‐Gertsch, Richard D. Gelber, Marco Colleoni, István Láng, Lucia Del Mastro, Laurence Gladieff, Manuela Rabaglio, Ian E. Smith, Jacquie Chirgwin, Aron Goldhirsch
200897
10
Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial
Journal of Clinical Oncology ·Henning T. Mouridsen, Aparna Keshaviah, Alan S. Coates, Manuela Rabaglio, Monica Castiglione‐Gertsch, Zhuoxin Sun, Beat Thürlimann, L. Mauriac, John Forbes, Robert Paridaens, Richard D. Gelber, Marco Colleoni, Ian Smith, Karen N. Price, Aron Goldhirsch
200793
11
Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: Design of the TEXT and SOFT trials
The Breast ·Meredith M. Regan, Olivia Pagani, Gini F. Fleming, Barbara Walley, Karen N. Price, Manuela Rabaglio, Rudolf Maibach, Barbara Ruepp, Alan S. Coates, Aron Goldhirsch, Marco Colleoni, Richard D. Gelber, Prudence A. Francis
201356
12
Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: Long-term follow up on IBCSG Trial IX
Annals of Oncology ·Stefan Aebi, Zijie Sun, Danielle Braun, Karen N. Price, Monica Castiglione‐Gertsch, Manuela Rabaglio, Richard D. Gelber, Diana Crivellari, Jurij Lindtner, Ray Snyder, Per Karlsson, Edda Simoncini, B.A. Gusterson, Giulia Viale, Meredith M. Regan, Alan S. Coates, Aron Goldhirsch
201146
13
Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are NOT suitable for a “standard chemotherapy regimen”: The CASA randomized trial
The Breast ·Diana Crivellari, Kathryn P. Gray, Silvia Dellapasqua, Fabio Puglisi, Karin Ribi, Karen N. Price, István Láng, Lorenzo Gianni, Simon Spazzapan, Graziella Pinotti, Jean-Marc Lüthi, Richard D. Gelber, Meredith M. Regan, Marco Colleoni, Monica Castiglione‐Gertsch, Rudolf Maibach, Manuela Rabaglio, Alan S. Coates, Aron Goldhirsch
201339
14
Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study
Cancer Research ·Shrushma Loi, Anita Giobbe-Hurder, Andrea Gombos, T Bachelot, Rina Hui, Giuseppe Curigliano, Mario Campone, Laura Biganzoli, H Bonnefoi, Guy Jérusalem, Rupert Bartsch, Manuela Rabaglio, Roswitha Kammler, Rudolf Maibach, Mark J. Smyth, Angelo Di Leo, Marco Colleoni, Giuseppe Viale, MM Regan, Fabrice André
201837
15
LBA40 Phase III double-blind randomized placebo controlled trial of atezolizumab in combination with carboplatin and paclitaxel in women with advanced/recurrent endometrial carcinoma
Annals of Oncology ·Nicoletta Colombo, Kenichi Harano, Emma Hudson, Francesca Galli, Yoland Antill, Chel Hun Choi, Manuela Rabaglio, Frederik Marmé, Edgar Petru, Chien‐Hung Lai, Elena Biagioli, L. Fariñas Madrid, Kazuhiro Takehara, K. Allan, Y.C. Lee, Elisa Piovano, Claudio Zamagni, Giulia Tasca, Annamaria Ferrero, M.P. Barretina Ginesta
202337
16
Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer
Annals of Oncology ·Per Karlsson, Zijie Sun, David A. Braun, Karen N. Price, Monica Castiglione‐Gertsch, Manuela Rabaglio, Richard D. Gelber, Diana Crivellari, J. Collins, Elizabeth Murray, Khalil Zaman, Marco Colleoni, B.A. Gusterson, Giuseppe Viale, Meredith M. Regan, Alan S. Coates, Aron Goldhirsch
201136
17
Treatment-Associated Musculoskeletal and Vasomotor Symptoms and Relapse-Free Survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial
Journal of Clinical Oncology ·Vered Stearns, Judith‐Anne W. Chapman, X. Cynthia, Matthew J. Ellis, James N. Ingle, Kathleen I. Pritchard, G. Thomas Budd, Manuela Rabaglio, George W. Sledge, Aurélie Le Maître, Jessica Kundapur, Pedro Emanuel Rubini Liedke, Lois E. Shepherd, Paul E. Goss
201433
18
Symptoms of endocrine treatment and outcome in the BIG 1-98 study
Breast Cancer Research and Treatment ·(unknown), Jens Huober, Bernard F. Cole, Manuela Rabaglio, Anita Giobbie‐Hurder, Justin J. Wu, Bent Ejlertsen, Hervé Bonnefoi, JF Forbes, Patrick Neven, István Láng, Ian Smith, Andrew Wardley, Karen N. Price, Aron Goldhirsch, Alan S. Coates, Marco Colleoni, Richard D. Gelber, Beat Thürlimann
201333
19
Controversies of adjuvant endocrine treatment for breast cancer and recommendations of the 2007 St Gallen conference
The Lancet Oncology ·Manuela Rabaglio, Stefan Aebi, Monica Castiglione‐Gertsch
200730
20
Autoantibodies against the platelet glycoproteins (GP) IIb/IIIa, Ia/IIa, and IV and partial deficiency in GPIV in a patient with a bleeding disorder and a defective platelet collagen interaction
Blood ·Jürg H. Beer, Manuela Rabaglio, Peter Berchtold, A. von Felten, KJ Clemetson, DA Tsakiris, Beate E. Kehrel, S Brandenberger
199328

About Manuela Rabaglio

Manuela Rabaglio is a scholar working on Genetics, Cancer Research, Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine, having authored 87 papers that have together received 2.1k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (19 papers), Breast Cancer Treatment Studies (17 papers), BRCA gene mutations in cancer (12 papers), Endometrial and Cervical Cancer Treatments (7 papers), Cancer Treatment and Pharmacology (7 papers), Advanced Breast Cancer Therapies (7 papers), Genetic factors in colorectal cancer (7 papers) and Metabolism, Diabetes, and Cancer (4 papers). The work is most often cited by research in Cancer Research (648 citations), Oncology (867 citations), Family Practice (55 citations), Genetics (539 citations) and Pulmonary and Respiratory Medicine (438 citations). Manuela Rabaglio has collaborated with scholars based in Switzerland, United States and Italy. Frequent co-authors include Alan S. Coates, Aron Goldhirsch, Richard D. Gelber, Karen N. Price, Beat Thürlimann, Marco Colleoni, John Forbes, Ian Smith, Meredith M. Regan and Bent Ejlertsen. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, Cancers and The Breast.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Monica CastiglioneBreakdown of academic impact, for papers by G Hoctin-BoesBreakdown of academic impact, for papers by J. N. IngleBreakdown of academic impact, for papers by Günther GruberBreakdown of academic impact, for papers by Eduardo R. PajonBreakdown of academic impact, for papers by Ted VandenbergBreakdown of academic impact, for papers by Marc ThillBreakdown of academic impact, for papers by A. De MatteisBreakdown of academic impact, for papers by Christoph TauschBreakdown of academic impact, for papers by D. Amoroso